These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Anti-platelet therapy in ischemic cerebrovascular disorder--clinical and hematological study].
    Author: Yoshii K, Seki Y, Aiba T, Tsukada T, Shiozawa R.
    Journal: No To Shinkei; 1985 Oct; 37(10):985-90. PubMed ID: 4074576.
    Abstract:
    Anti-platelet therapy (Aspirin 250 mg/every other day approximately 1000 mg/day + Dipyridamole 150 mg/day) was performed on 51 patients with ischemic cerebrovascular disorders (ICVD). Among these patients, 41 cases showed no recurrence of ICVD attack, whereas the remaining 10 cases had re-attacks. These 2 groups were compared from the viewpoint of various risk factors and other clinical findings: e.g. CT scan and angiographic appearance. But there was no statistically significant difference between them. Platelet aggregability and platelet survival time were examined in twenty-eight patients out of cases. We used a simple nonradioisotope technic for the determination of platelet survival time. Platelet survival time was shortened in 22 of 28 (79%) patients. On the other hand, platelet aggregability was found to have no definite tendency. In 9 of 10 cases, platelet survival time was revealed to be prolonged several months after administration of anti-platelet drugs. There was no re-attack in 7 of these 9 patients. Some reports also showed that platelet survival time was shortened in various thromboembolism and recovered by anti-platelet drugs. Measurement of platelet survival time is thought to be an important method as to the indication and the monitoring of anti-platelet therapy.
    [Abstract] [Full Text] [Related] [New Search]